Justin C Boucher
Overview
Explore the profile of Justin C Boucher including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
214
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nagy M, Plaza-Rojas L, Boucher J, Kostenko E, Austin A, Tarhini A, et al.
J Immunother Cancer
. 2025 Feb;
13(2).
PMID: 40010774
Background: In the tumor microenvironment (TME), hypoxia stands as a significant factor that modulates immune responses, especially those driven by T cells. As T cell-based therapies often fail to work...
2.
Boucher J, Li G, Kotani H, Cabral M, Morrissey D, Lee S, et al.
Cancer Immunol Res
. 2024 Nov;
12(12):1808.
PMID: 39540853
No abstract available.
3.
Kotani H, Yamano T, Boucher J, Sato S, Sakaguchi H, Fukuda K, et al.
Exp Hematol Oncol
. 2024 Sep;
13(1):94.
PMID: 39334463
Precision medicine has drastically changed cancer treatment strategies including KRAS-mutant cancers which have been undruggable for decades. While intrinsic or acquired treatment resistance remains unresolved in many cases, epigenome-targeted therapy...
4.
Kotani H, Oshima H, Boucher J, Yamano T, Sakaguchi H, Sato S, et al.
J Biomed Sci
. 2024 Jul;
31(1):68.
PMID: 38992694
Background: KRAS mutations frequently occur in cancers, particularly pancreatic ductal adenocarcinoma, colorectal cancer, and non-small cell lung cancer. Although KRAS inhibitors have recently been approved, effective precision therapies have not...
5.
Boucher J, Shrestha B, Vishwasrao P, Leick M, Cervantes E, Ghafoor T, et al.
Mol Ther Oncolytics
. 2023 Dec;
31:100751.
PMID: 38075241
CD33 and CD123 are expressed on the surface of human acute myeloid leukemia blasts and other noncancerous tissues such as hematopoietic stem cells. On-target off-tumor toxicities may limit chimeric antigen...
6.
Perez C, Plaza-Rojas L, Boucher J, Nagy M, Kostenko E, Prajapati K, et al.
J Leukoc Biol
. 2023 Nov;
115(2):306-321.
PMID: 37949818
The role of natural killer group 2D (NKG2D) in peripheral T cells as a costimulatory receptor is well established. However, its contribution to T cell thymic education and functional imprint...
7.
Boucher J, Yu B, Li G, Shrestha B, Sallman D, Landin A, et al.
J Immunother
. 2022 Nov;
46(1):5-13.
PMID: 36378147
Higher γδ T cell counts in patients with malignancies are associated with better survival. However, γδ T cells are rare in the blood and functionally impaired in patients with malignancies....
8.
Vishwasrao P, Li G, Boucher J, Smith D, Hui S
Cancers (Basel)
. 2022 Mar;
14(5).
PMID: 35267549
Engineered T cells expressing chimeric antigen receptors (CARs) on their cell surface can redirect antigen specificity. This ability makes CARs one of the most promising cancer therapeutic agents. CAR-T cells...
9.
Roselli E, Boucher J, Li G, Kotani H, Spitler K, Reid K, et al.
J Immunother Cancer
. 2021 Oct;
9(10).
PMID: 34706886
Background: Co-stimulatory signals regulate the expansion, persistence, and function of chimeric antigen receptor (CAR) T cells. Most studies have focused on the co-stimulatory domains CD28 or 4-1BB. CAR T cell...
10.
Boucher J, Davila M
Cancer J
. 2021 Mar;
27(2):92-97.
PMID: 33750067
The US Food and Drug Administration has approved 3 chimeric antigen receptor (CAR) T-cell therapies. For continued breakthroughs, novel CAR designs are needed. This includes different antigen-binding domains such as...